Clinical Trial Update: Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor [Phase 3]

View source ↗

Summary

Phase III study evaluating BKM120 (buparlisib) or placebo with fulvestrant in postmenopausal women with hormone receptor–positive, HER2-negative locally advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BKM120 (Buparlisib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2020-06-18